印度、日本、韓國疫情加劇,疫苗股集體走強!
格隆匯4月21日丨A股疫苗股集體走強,西藏藥業漲停,康華生物漲超9%,萬泰生物、華北製藥、沃森生物、智飛生物漲超4%,未名生物、復星醫藥和康希諾漲超2%。印度、日本和韓國等疫情再度惡化。過去24小時內,印度新增新冠肺炎確診病例295041例,新增死亡病例2023例,新增確診病例再次打破該國自疫情以來的最高紀錄,且連續第7天保持在20萬以上。日本方面,東京都知事小池百合子考慮4月29日至5月9日期間進入緊急狀態。 韓國過去24小時新增731例新冠確診病例,時隔一週再度超過700例,在第三波大流行餘波尚未平息的情況下,疫情已呈現第四波大流行。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.